Alnylam Pharmaceuticals, Inc.

Biotech pioneer of RNA interference (RNAi) medicines that silence disease-causing genes

What Alnylam Pharmaceuticals does

Alnylam Pharmaceuticals develops and sells medicines based on RNA interference (RNAi) — a way of switching off specific disease-causing genes before they can make harmful proteins. It has built a commercial portfolio of approved therapies for rare and increasingly common conditions, including hereditary and wild-type ATTR amyloidosis, acute hepatic porphyria, and high cholesterol, and runs a deep pipeline across cardiometabolic, central-nervous-system and other diseases.

How Alnylam Pharmaceuticals makes money

Alnylam earns revenue mainly from selling its own approved RNAi drugs (such as ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO) to patients through specialty distribution, plus royalties and milestone payments from partners like Novartis, Regeneron, Roche and Sanofi that license or co-develop its technology. Growth comes from expanding each drug into larger patient populations and advancing new candidates through the pipeline.

Products & services

• ONPATTRO / AMVUTTRA (ATTR amyloidosis)
• GIVLAARI (acute hepatic porphyria)
• OXLUMO (primary hyperoxaluria)
• Leqvio/inclisiran (cholesterol, with Novartis)
• RNAi drug-discovery platform